Drug–drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS-Reference-Cited by-同舟云学术

Drug–drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS

Published:2023-07-24 Issue: Volume: Page:1-7
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Qin Fuhong¹,Wang Huiling²,Li Meng³,Zhuo Shengnan³,Liu Wei³

Affiliation:

1. Department of Pharmacy, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China

2. School of Pharmaceutical Sciences, Zhengzhou Railway Vocational and Technical College, Zhengzhou, China

3. School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2239156

Reference33 articles.

1. U.S. Food and Drug Administration. Coronavirus (COVID-19) | drugs: FDA authorizes first oral antiviral for treatment of COVID-19. Accessed 10 Feb 2023. https://www.fda.gov/drugs/emergency-preparedness-drugs/emergency-use-authorizations-drugs-and-non-vaccine-biological-products.

2. Nirmatrelvir Plus Ritonavir: First Approval

3. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

4. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients

5. Recommendations for the Management of Drug–Drug Interactions Between the COVID ‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review;Infectious Diseases and Therapy;2024-04-12